Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Acquired by Van ECK Associates Corp

Van ECK Associates Corp lifted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 58.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,472 shares of the medical equipment provider's stock after acquiring an additional 21,604 shares during the period. Van ECK Associates Corp owned 0.08% of Lantheus worth $6,469,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Farallon Capital Management LLC raised its holdings in Lantheus by 595.3% in the first quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider's stock valued at $92,316,000 after buying an additional 1,269,900 shares during the period. Swedbank AB acquired a new position in shares of Lantheus during the 1st quarter valued at $26,346,000. Westfield Capital Management Co. LP boosted its position in Lantheus by 25.3% during the 1st quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider's stock worth $121,867,000 after purchasing an additional 394,837 shares during the period. Vanguard Group Inc. increased its holdings in Lantheus by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock valued at $458,271,000 after purchasing an additional 389,828 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in Lantheus in the second quarter valued at about $26,794,000. 99.06% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Lantheus news, Director Gerard Ber sold 15,500 shares of the firm's stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 2.10% of the company's stock.

Wall Street Analyst Weigh In

LNTH has been the subject of several analyst reports. Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price for the company. Truist Financial restated a "buy" rating and issued a $120.00 price target (down previously from $135.00) on shares of Lantheus in a report on Friday. Leerink Partners lifted their price objective on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research note on Thursday, July 11th. B. Riley upped their target price on shares of Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a research note on Thursday, July 25th. Finally, JMP Securities lowered their price target on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating for the company in a report on Thursday. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $122.50.

Lantheus Stock Down 1.9 %

Shares of LNTH traded down $1.68 during midday trading on Friday, hitting $86.64. The company had a trading volume of 865,899 shares, compared to its average volume of 989,719. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The company's 50 day moving average price is $107.71 and its 200 day moving average price is $95.52. The stock has a market cap of $6.02 billion, a price-to-earnings ratio of 14.66 and a beta of 0.51.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.08. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business had revenue of $378.73 million for the quarter, compared to analyst estimates of $373.58 million. On average, equities research analysts predict that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.